We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Drug May Reduce Heart Attack Damage

By LabMedica International staff writers
Posted on 22 Sep 2008
Cardiovascular disease researchers have discovered a compound that shows promise as a drug to reduce the extent of damage caused to the heart muscle during a heart attack.

Investigators at Stanford University (Palo Alto, CA, USA) and at Indiana University (Indianapolis, IN, USA) identified mitochondrial aldehyde dehydrogenase 2 (ALDH2) as an enzyme whose activation correlated with reduced ischemic heart damage in rodent models. This finding prompted the search for drug candidates that could activate ALDH2.

The researchers reported in the September 12, 2008, issue of the journal Science that by employing a high-throughput screening assay they were able to show that the synthetic compound Alda-1 directly bound ALDH2, enhanced its activity, and reduced cardiac damage by 60% when injected directly into the hearts of live healthy rats five minutes before the induction of a simulated heart attack caused by blockage of blood flow to the heart.

"The idea was to find a small molecule that could bypass the signaling process and activate the enzyme directly," said contributing author Dr. Thomas D. Hurley, professor of biochemistry and molecular biology at Indiana University. "Although the Alda-1 molecule reduced heart tissue damage in laboratory tests, years of work will be necessary to refine the compound into a version that would be potentially effective and safe for human use."

That benefit could extend to about 40% percent of people of East Asian descent who carry a mutated form of the ALDH2 enzyme, which puts them at increased risk of cardiovascular damage.

Related Links:

Stanford University
Indiana University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Hematology Consumables
Bioblood Devices
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
22 Sep 2008  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
22 Sep 2008  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
22 Sep 2008  |   BioResearch